ArticleRheumatology international2026
Clinical and serological features according to anti-DFS70 antibody status in undifferentiated connective tissue disease: a retrospective cross-sectional study.
Article in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to compare demographic, clinical, laboratory, and autoantibody profiles between anti-dense fine speckled 70 (DFS70)-positive and -negative patients with undifferentiated connective tissue disease (UCTD). We retrospectively analyzed 284 UCTD patients followed at a tertiary rheumatology centre between January 2017 and December 2024. Patients fulfilling established classification criteria for a defined connective tissue disease were excluded. Patients were stratified according to anti-DFS70 status. Group comparisons were performed, and the Benjamini-Hochberg procedure was applied to control the false discovery rate. A multivariable logistic regression model was additionally used to evaluate the potential confounding effect of hydroxychloroquine use. Of 284 patients, 75 (26.4%) were anti-DFS70 positive and 209 (73.6%) were negative. After false discovery rate correction, arthritis/arthralgia was more frequent in the anti-DFS70-negative group than in the positive group (81.8% vs. 61.3%, adjusted p = 0.034), as was homogeneous ANA pattern (33.5% vs. 12.0%, adjusted p = 0.034). In multivariable analysis, homogeneous ANA pattern remained associated with anti-DFS70 negativity after adjustment for hydroxychloroquine use (OR 2.71, 95% CI 1.16-6.30, p = 0.021), whereas arthritis/arthralgia did not remain statistically significant (OR 1.92, 95% CI 0.95-3.90, p = 0.071). Anti-DFS70 negativity in UCTD was associated with homogeneous ANA pattern. Clinical associations, particularly arthritis/arthralgia, should be interpreted cautiously because of potential confounding by treatment exposure. Further prospective studies are warranted to clarify the clinical significance of anti-DFS70 status in UCTD.
Indexed as
Identifiers
42911409What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.